Aspira Women's Health Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Aspira Women's Health Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $343.0K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $4.0K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $87.00M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.18M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $2.07M | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | $6.81M | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | $4.65M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.54M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.05M | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $3.12M | Mar 28, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.22M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $9.18M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $9.15M | Mar 27, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.92M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $5.48M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $5.26M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $4.32M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $1.16M | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | $3.06M | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | $1.24M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.20M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($89.0K) | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $207.0K | Mar 28, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.78M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($13.09M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($16.69M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($29.89M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | ($7.78M) | Oct 26, 2023 |
| FY2022 | Jun 30, 2022 | ($8.24M) | Oct 26, 2023 |
| FY2022 | Mar 31, 2022 | ($9.27M) | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | ($31.66M) | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | ($17.91M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($15.24M) | Mar 31, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.91M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($16.28M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($18.85M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($31.14M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | ($8.58M) | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | ($32.60M) | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | ($17.98M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($15.28M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($11.33M) | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | ($10.44M) | Mar 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.88M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $3.27M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $4.04M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $5.92M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $2.16M | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | $5.31M | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | $2.10M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.02M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $550.0K | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $837.0K | Mar 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.03M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($12.11M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($15.89M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($31.07M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | ($23.99M) | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | ($27.40M) | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | ($14.73M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($12.97M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($9.37M) | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | ($8.13M) | Mar 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.0K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $37.0K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $24.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $232.0K | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $158.0K | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | $184.0K | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | $490.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $133.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $113.0K | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $60.0K | Mar 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.46M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $5.49M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $6.26M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $17.37M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $23.94M | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | $41.08M | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | $19.61M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $13.83M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $11.41M | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $7.50M | Mar 28, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.39M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $8.05M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $8.63M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $10.39M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $12.76M | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | $10.91M | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | $9.89M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.09M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.26M | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $4.09M | Mar 28, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.93M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($2.56M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($2.37M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.98M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $11.18M | Oct 26, 2023 |
| FY2022 | Jun 30, 2022 | $14.12M | Oct 26, 2023 |
| FY2022 | Mar 31, 2022 | $21.74M | Oct 26, 2023 |
| FY2023 | Dec 31, 2021 | $30.17M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $9.72M | Oct 26, 2023 |
| FY2021 | Dec 31, 2019 | $8.74M | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($544.18M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($531.40M) | Apr 1, 2026 |
| FY2023 | Dec 31, 2023 | ($518.30M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($501.61M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | ($497.02M) | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | ($471.73M) | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | ($440.07M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($422.16M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($406.92M) | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | ($396.05M) | Mar 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.76M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $1.77M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $2.60M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $13.31M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $20.55M | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | $37.18M | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | $16.63M | Mar 31, 2022 |
| FY2017 | Dec 31, 2017 | $5.54M | Mar 13, 2018 |
| FY2017 | Dec 31, 2016 | $5.24M | Mar 13, 2018 |
| FY2017 | Dec 31, 2015 | $18.64M | Mar 13, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.28M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $1.51M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $1.60M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.72M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.92M | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | $4.12M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.29M | Mar 31, 2021 |
| FY2011 | Dec 31, 2010 | $7.00M | Mar 27, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | (1) | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | (4) | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 28, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | (1) | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | (4) | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 28, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43.48M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 17.41M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 10.65M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 8.31M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | 8.30M | Oct 26, 2023 |
| FY2022 | Dec 31, 2021 | 7.48M | Oct 26, 2023 |
| FY2021 | Dec 31, 2020 | 104.62M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 97.29M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 75.50M | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | 60.04M | Mar 28, 2019 |